<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04785547</url>
  </required_header>
  <id_info>
    <org_study_id>FORUM Add-on Blina post TX</org_study_id>
    <nct_id>NCT04785547</nct_id>
  </id_info>
  <brief_title>ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT</brief_title>
  <official_title>A Phase II Study of Blincyto in Children With CD19+ Precursor B-lineage ALL and MRD-Positivity Before and/or Following First Allogeneic HSCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Christina Peters</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Anna Kinderkrebsforschung</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II trial of continuous intravenous infusion of Blincyto given over a 28-day cycle.&#xD;
      Starting day for patients who are MRD-positive before HSCT is between day +60 and day +100&#xD;
      and for patients who become MRD-positive post HSCT it is between day +60 and day +360 post&#xD;
      HSCT.&#xD;
&#xD;
      Patients will be evaluated for response at day +28 (+4 days) (bone marrow morphology and MRD&#xD;
      analysis - defined by PCR/FLOW-techniques) after start of Blincyto-treatment at the end of&#xD;
      first Blincyto infusion and at regular post-TX-checks (according to FORUM: days +28, +60,&#xD;
      +100, +180 and +360 after HSCT).&#xD;
&#xD;
      The dose of Blincyto used in this trial will be 15 mcg/m2/day for 28 days&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      6.2.1 Screening / Pretreatment * The screening process begins on the date the subject (or&#xD;
      legally acceptable representative) signs the IRB/EC approved ICF and assent form and&#xD;
      continues until enrollment. Informed consent and assent must be obtained before completing&#xD;
      any study-specific procedures. After written informed consent and assent have been obtained,&#xD;
      subjects will be screened in order to assess eligibility for study participation. Only&#xD;
      eligible subjects who meet the inclusion/exclusion criteria listed in Section 4 will be&#xD;
      enrolled in the study. The total screening window is up to 14 days. If a subject has not met&#xD;
      all eligibility criteria at the end of the 14-day window, the subject will be classified as a&#xD;
      screen failure on the subject screening log. Subjects who screen fail may be eligible to&#xD;
      rescreen one time per Section 6.2.2.&#xD;
&#xD;
      The following assessments/procedures are to be completed during the screening period at time&#xD;
      points designated in the Schedule of Assessments (Table 3):&#xD;
&#xD;
        -  Confirmation that the Informed Consent Form and Assent Form have been signed&#xD;
&#xD;
        -  Product History Form for subjects who were enrolled in a previous Amgen Blincyto study&#xD;
&#xD;
        -  Relevant medical history: including all data which are documented in FORUM trial&#xD;
&#xD;
        -  Review of inclusion/exclusion criteria&#xD;
&#xD;
        -  Physical examination&#xD;
&#xD;
        -  Local laboratory assessments within 7 days prior to treatment start:&#xD;
&#xD;
        -  Chemistry&#xD;
&#xD;
        -  Coagulation&#xD;
&#xD;
        -  Hematology (CBC with differential)&#xD;
&#xD;
        -  Bone marrow aspirate (morphological and MRD assessment)&#xD;
&#xD;
           · Lumbar puncture&#xD;
&#xD;
        -  Serious Adverse Event reporting 6.2.2 Rescreening Subjects who are unable to complete or&#xD;
           meet eligibility at the initial screening will be permitted to rescreen once, provided&#xD;
           study recruitment has not closed. Upon signing a new Informed Consent Form and Assent&#xD;
           Form, a new 14-day screening window will begin. Subjects will retain the same subject&#xD;
           identification number assigned at the original screening.&#xD;
&#xD;
      After reconsenting, all screening procedures, including the bone marrow aspirate, must be&#xD;
      repeated. However, previous bone marrow aspirate/biopsy taken within 14 days of the planned&#xD;
      treatment start of Blincyto can be used to determine eligibility.&#xD;
&#xD;
      6.2.3 Treatment The following procedures will be completed during day 1 to day 29 at the&#xD;
      times designated in the Schedule of Assessments (Table 3). For assessments performed at day&#xD;
      1, all study procedures should be completed prior to the initiation of Blincyto therapy,&#xD;
      unless noted otherwise.&#xD;
&#xD;
        -  Physical examination (D1 of each treatment cycle), prior to infusion start&#xD;
&#xD;
        -  Bone marrow aspirate/biopsy (morphological and MRD assessment): day 29, not mandatory in&#xD;
           case of documented disease progression or relapse&#xD;
&#xD;
        -  Chemistry, Coagulation, Hematology (Complete blood test (CBC) with differential)&#xD;
&#xD;
        -  day 1: +6h after the first dose of Blincyto&#xD;
&#xD;
        -  day 2: any time&#xD;
&#xD;
        -  day 3: any time&#xD;
&#xD;
        -  In addition, hematology only: day 29, not mandatory in case of documented disease&#xD;
           progression or relapse.&#xD;
&#xD;
        -  Immunoglobulins (IgG only)&#xD;
&#xD;
        -  Day 1, prior to infusion start&#xD;
&#xD;
        -  Day 29, after end of infusion&#xD;
&#xD;
        -  Vital signs (pulse and temperature only), at the following time points:&#xD;
&#xD;
        -  Day 1, prior to infusion start&#xD;
&#xD;
        -  Day 15 and day 29 (any time)&#xD;
&#xD;
        -  Any other time as deemed necessary by the investigator per institutional guidelines&#xD;
&#xD;
        -  Neurological examination (eg, finger-nose and/or writing test, as appropriate for age):&#xD;
&#xD;
        -  day 1, prior to infusion start&#xD;
&#xD;
        -  day 2 and day 3, any time&#xD;
&#xD;
        -  Any other time as deemed necessary by the investigator per institutional guidelines&#xD;
&#xD;
        -  Serious Adverse Event reporting 6.2.4 Safety Follow-up Visit(s) / End of Study Visit&#xD;
&#xD;
      All subjects, including subjects who withdraw early, should complete a safety follow-up visit&#xD;
      30 days (± 4 days) after the last dose of Blincyto. The following procedures will be&#xD;
      completed at the visit:&#xD;
&#xD;
        -  Physical examination&#xD;
&#xD;
        -  Local laboratory assessments:&#xD;
&#xD;
        -  Chemistry&#xD;
&#xD;
        -  Coagulation&#xD;
&#xD;
        -  Hematology (CBC with differential)&#xD;
&#xD;
        -  Immunoglobulins (IgG only)&#xD;
&#xD;
        -  Urine or serum pregnancy test (female adolescents of childbearing potential only), if&#xD;
           applicable&#xD;
&#xD;
        -  Serious Adverse Event reporting 6.2.5 Long-term Follow-up All subjects will be followed&#xD;
           in the long-term follow-up portion of the study for OS.&#xD;
&#xD;
      Subjects in remission will also be followed for duration of response. Following the safety&#xD;
      follow-up visit, subjects will be followed every 6 months (± 2 weeks) until 14 months after&#xD;
      the first dose of Blincyto to assess disease status. The following procedures will be&#xD;
      completed for subjects who remain in remission:&#xD;
&#xD;
        -  Disease/Survival status&#xD;
&#xD;
        -  Bone marrow aspirate/biopsy (morphological and MRD assessment) at day +180 post HSCT and&#xD;
           day 360 post HSCT.&#xD;
&#xD;
        -  Hematology (neutrophils and platelets) 6.2.6 Lumbar Puncture to Examine Cerebrospinal&#xD;
           Fluid In case of clinical signs of CNS-disease a lumbar puncture will be performed as&#xD;
           outlined in the Schedule of Assessments (Table 3) to assess for possible leukemic&#xD;
           involvement of the CNS. CSF cell count, glucose, and protein will be measured at the&#xD;
           local laboratory as part of the examination. Additional investigations of the CSF should&#xD;
           be performed as clinically appropriate.&#xD;
&#xD;
      If an Ommaya reservoir is in place and there is no evidence of blockage of CSF flow in the&#xD;
      spinal canal, withdrawal of a sample through the Ommaya reservoir is permitted.&#xD;
&#xD;
      6.2.7 Bone Marrow Biopsy / Aspiration&#xD;
&#xD;
      Bone marrow will be used for hematological assessment and for evaluation of MRD. The&#xD;
      following samples will be obtained for cytomorphological assessment and MRD measurement by a&#xD;
      local laboratory:&#xD;
&#xD;
        -  Cytomorphology/percentage of blasts: bone marrow aspirates at screening, at the end of&#xD;
           each treatment cycle, and every 6 months during long-term follow-up for subjects in&#xD;
           remission only, until relapse.&#xD;
&#xD;
        -  MRD: Aliquots at screening will be collected and analyzed. Aliquots for each subsequent&#xD;
           bone marrow assessment may be collected and analyzed, if applicable.&#xD;
&#xD;
      In case of insufficient quality of the bone marrow material at the end of each treatment&#xD;
      cycle, a repeat bone marrow assessment should be performed prior to treatment start in the&#xD;
      next cycle or at the safety follow-up visit if the subject has not progressed and no further&#xD;
      treatment cycles are to be administered.&#xD;
&#xD;
      The degree of bone marrow infiltration defined by the percentage of leukemic blasts in bone&#xD;
      marrow will be evaluated by local laboratories per cytomorphology and flow cytometry&#xD;
      immunophenotyping. During screening the B-precursor phenotype with CD19 positivity (at least&#xD;
      partial) should be confirmed for inclusion.&#xD;
&#xD;
      6.2.8 Laboratory Assessments The analytes for all laboratory tests used throughout this study&#xD;
      are listed in the table below. All screening and on-study laboratory samples will be&#xD;
      collected and processed at the investigator's local laboratory and analyzed locally. Standard&#xD;
      laboratory tests will be performed according to institutional guidelines. The date and time&#xD;
      of sample collection will be recorded in the source documents at the site. Blood draws should&#xD;
      not be done via the central venous access. Exception: If a permanent central line with more&#xD;
      than one lumen is used, blood draws can be done via the lumen that is not used for drug&#xD;
      administration. Table 4 outlines the specific analytes that will be assessed during the study&#xD;
      at time points outlined in the Schedule of Assessments (Table 3). Any additional follow-up&#xD;
      laboratory testing should be performed per standard of care for the treatment of ALL and&#xD;
      according to ALL SCTped 2012 FORUM-study.&#xD;
&#xD;
      *Numeration as per protocol&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of MRD-negativity</measure>
    <time_frame>Patients may receive 2 cycles of treatment. A single cycle of treatment is 28 days (4 weeks) of continuous infusion. Each cycle of treatment is separated by a 14 day (2 weeks) treatment-free interval.</time_frame>
    <description>Rate of MRD-negativity is defined as &lt; 0.01 percent (%) by flow cytometry and &lt; 10-4 by PCR after first and second Blincyto cycle</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>ALL, Childhood</condition>
  <condition>Minimal Residual Disease</condition>
  <arm_group>
    <arm_group_label>Blincyto</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blincyto is given over a 28-day cycle. Starting day for patients, who are MRD-positive before HSCT is between day +60 and day +100 and for patients, who become MRD-positive post HSCT it is between day +60 and day +360 post HSCT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blinatumomab</intervention_name>
    <description>15 mcg/m2/day for 28 days</description>
    <arm_group_label>Blincyto</arm_group_label>
    <other_name>Blincyto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients participating in ALL SCTped 2012 FORUM;&#xD;
&#xD;
          -  Age: &gt; 0.5 years and &lt; 21 years;&#xD;
&#xD;
          -  B-precursor ALL with &lt; 5% blasts in the bone marrow (M1 bone marrow) and CD19+ minimal&#xD;
             residual disease (MRD) before and/or following allogeneic HSCT;&#xD;
&#xD;
          -  Indication for first allogeneic HSCT was CD19+ ALL in first, second or third&#xD;
             remission;&#xD;
&#xD;
          -  Allogeneic Hematopoietic Stem Cell Transplant (HSCT): at first dose of Blincyto&#xD;
             patients must be at least &gt; 60 days post-SCT and without evidence of grade 2 or higher&#xD;
             acute GVHD and off systemic immunosuppression (tapering allowed) and at least 4 weeks&#xD;
             after last donor lymphocyte infusion (DLI);&#xD;
&#xD;
          -  Performance-Status (Karnovsky/Lansky): above 50%;&#xD;
&#xD;
          -  Written consent of the parents/legal guardian and, if necessary, the minor patient via&#xD;
             &quot;Informed Consent Form&quot;;&#xD;
&#xD;
          -  No pregnancy;&#xD;
&#xD;
          -  No secondary malignancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not fulfill the inclusion criteria;&#xD;
&#xD;
          -  The whole protocol or essential parts are declined either by patient himself/herself&#xD;
             or the respective legal guardian;&#xD;
&#xD;
          -  Malformation syndromes;&#xD;
&#xD;
          -  Renal impairment (&lt; 30% of normal glomerular filtration rate);&#xD;
&#xD;
          -  Severe pulmonary, hepatic or cardiac impairment due to toxicity or infection (&gt; CTCAE&#xD;
             grade 3);&#xD;
&#xD;
          -  Recent episode of seizures or posterior reversible encephalopathy syndrome in the past&#xD;
             30 days;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Peters, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St.Anna Kinderspital, Vienna, Austria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christina Peters, MD</last_name>
    <phone>+43(1)40170 3106</phone>
    <email>christina.peters@stanna.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Anna Kinderspital</name>
      <address>
        <city>Vienna</city>
        <state>Austria(AUT)</state>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Peters, MD</last_name>
      <phone>+43 (1) 40170 3106</phone>
      <email>christina.peters@stanna.at</email>
    </contact>
    <investigator>
      <last_name>Herbert Pichler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg (UZ Leuven)</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marleen Renard, MD</last_name>
      <email>marleen.renard@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>An Michiels</last_name>
      <email>an.michiels@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Marleen Renard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Motol University Hospital Prague</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Petr Sedlacek, MD</last_name>
      <email>petr.sedlacek@fnmotol.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Sedlacek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Rosenkrantz Segelcke Ifversen, MD</last_name>
      <email>Marianne.Ifversen@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Marianne Rosenkrantz Segelcke Ifversen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré, Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Hugues Dalle, MD</last_name>
      <email>jean-hugues.dalle@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Hugues Dalle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Sophia Children's Hospital Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dikaia-Eleni Ionnidou, MD</last_name>
      <email>elda.ioannidou@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dikaia-Eleni Ionnidou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Gerardo Monza</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adriana Balduzzi, MD</last_name>
      <email>abalduzzi@fondazionembbm.it</email>
    </contact>
    <investigator>
      <last_name>Adriana Balduzzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesù Roma</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franco Locatelli, MD</last_name>
      <email>franco.locatelli@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Franco Locatelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen Büchner, MD</last_name>
      <email>jocbuc@ous-hf.no</email>
    </contact>
    <investigator>
      <last_name>Jochen Büchner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nicolaus Copernicus University Collegium Medicum</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mariusz Wysocki, MD</last_name>
      <email>m.wysocki@cm.umk.pl</email>
    </contact>
    <contact_backup>
      <last_name>Jan Styczyński, MD</last_name>
      <email>jstyczynski@cm.umk.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Mariusz Wysocki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Styczyński, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lublin, Medical Academy</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katarzyna Drabko, MD</last_name>
      <email>katarzynadrabko@umlub.pl</email>
    </contact>
    <investigator>
      <last_name>Katarzyna Drabko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Medical Sciences Poznan</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacek Wachowiak, MD</last_name>
      <email>jwachow@ump.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Jacek Wachowiak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinika Transplantacji Szpiku</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Krzysztof Kalwak, MD</last_name>
      <email>krzysztof.kalwak@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Krzysztof Kalwak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Svec, MD</last_name>
      <email>peter.svec@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Peter Svec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cristina Díaz de Heredia, MD</last_name>
      <email>crdiaz@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Cristina Díaz de Heredia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Anna Kinderkrebsforschung</investigator_affiliation>
    <investigator_full_name>Prof. Christina Peters</investigator_full_name>
    <investigator_title>Univ.-Prof. Dr. Christina Peters</investigator_title>
  </responsible_party>
  <keyword>MRD Positivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm, Residual</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blinatumomab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

